CO2018012941A2 - Polymorphic forms of 3- [2-butyl-1- (2-diethylamino-ethyl-1h-benzoimidazol-5-yl] -n-hydroxy-acrylamide and their uses - Google Patents
Polymorphic forms of 3- [2-butyl-1- (2-diethylamino-ethyl-1h-benzoimidazol-5-yl] -n-hydroxy-acrylamide and their usesInfo
- Publication number
- CO2018012941A2 CO2018012941A2 CONC2018/0012941A CO2018012941A CO2018012941A2 CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2 CO 2018012941 A CO2018012941 A CO 2018012941A CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2
- Authority
- CO
- Colombia
- Prior art keywords
- benzoimidazol
- diethylamino
- acrylamide
- hydroxy
- butyl
- Prior art date
Links
- JHDKZFFAIZKUCU-UHFFFAOYSA-N 3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=CC1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen Polimorfos de Formas cristalinas del 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida. También se presentan composiciones farmacéuticas y los usos de las mismas, Formas compuestas y composiciones, para el tratamiento de enfermedades y afecciones.Polymorphs of crystalline forms of 3- [2-butyl-1- (2-diethylamino-ethyl) -1H-benzoimidazol-5-yl] -N-hydroxy-acrylamide are described. Pharmaceutical compositions and their uses, Composite forms and compositions, for the treatment of diseases and conditions are also presented.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330673P | 2016-05-02 | 2016-05-02 | |
| PCT/US2017/030414 WO2017192451A1 (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018012941A2 true CO2018012941A2 (en) | 2018-12-28 |
Family
ID=60203321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0012941A CO2018012941A2 (en) | 2016-05-02 | 2018-11-29 | Polymorphic forms of 3- [2-butyl-1- (2-diethylamino-ethyl-1h-benzoimidazol-5-yl] -n-hydroxy-acrylamide and their uses |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10626092B2 (en) |
| EP (2) | EP3939966A1 (en) |
| JP (1) | JP2019514905A (en) |
| KR (1) | KR20190005904A (en) |
| CN (1) | CN109414425A (en) |
| AR (1) | AR108257A1 (en) |
| AU (1) | AU2017261218A1 (en) |
| BR (1) | BR112018072439A2 (en) |
| CA (1) | CA3022011A1 (en) |
| CL (1) | CL2018003109A1 (en) |
| CO (1) | CO2018012941A2 (en) |
| EA (1) | EA201892341A1 (en) |
| ES (1) | ES2886495T3 (en) |
| IL (1) | IL262578A (en) |
| MA (1) | MA44880A (en) |
| MX (1) | MX382095B (en) |
| PH (1) | PH12018502296B1 (en) |
| SG (1) | SG11201809471UA (en) |
| TW (1) | TW201741286A (en) |
| WO (1) | WO2017192451A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018157742A1 (en) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Crystalline form of salt of sb-939, preparation method therefor, and use |
| WO2019126282A1 (en) | 2017-12-19 | 2019-06-27 | Assia Chemical Industries Ltd. | Crystalline polymorphs of pracinostat and pracinostat salts |
| WO2019149262A1 (en) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Crystal form of sb-939, preparation method and use thereof |
| US20230159468A1 (en) | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (en) | 1974-11-20 | 1976-06-18 | Delalande Sa | 5-carboxyalkyl-benzimidazole derivs - with analgesic, sedative, hypertensive or hypotensive, bronchodilatory, anticholinergic and vasodilatory activity |
| CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
| SE9804212D0 (en) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN1358094A (en) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | Approaches to treating chronic pain with MEK inhibitors |
| JP2003504401A (en) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Method for treating chronic pain using MEK inhibitor |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| SK13752001A3 (en) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Fused-ring compounds and use thereof as drugs |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
| HUP0400651A2 (en) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors and pharmaceutical compositions containing them |
| PA8535601A1 (en) | 2000-12-21 | 2002-11-28 | Pfizer | BENZIMIDAZOL AND PIRIDILIMIDAZOL DERIVATIVES AS LIGANDOS FOR GABAA |
| WO2003000682A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (en) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS |
| CA2473505A1 (en) | 2002-02-07 | 2003-08-14 | Ellen M. Leahy | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
| DE10239042A1 (en) | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| MY142589A (en) | 2003-09-22 | 2010-12-15 | S Bio Pte Ltd | Benzimidazole derivatives : preparation and pharmaceutical applications |
| WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| CA2540459C (en) * | 2005-09-08 | 2014-02-18 | S*Bio Pte Ltd | Benzimidazole compounds and uses in treating proliferative disorders |
| PL1937650T3 (en) * | 2005-09-08 | 2011-11-30 | Mei Pharma Inc | Heterocyclic compounds |
| EP2131840B1 (en) | 2007-03-07 | 2018-10-17 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| EP3662911A1 (en) | 2012-10-30 | 2020-06-10 | MEI Pharma, Inc. | Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds) |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/en unknown
- 2017-05-01 ES ES17793075T patent/ES2886495T3/en active Active
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 US US16/098,435 patent/US10626092B2/en not_active Expired - Fee Related
- 2017-05-01 MX MX2018013349A patent/MX382095B/en unknown
- 2017-05-01 EA EA201892341A patent/EA201892341A1/en unknown
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 MA MA044880A patent/MA44880A/en unknown
- 2017-05-01 CA CA3022011A patent/CA3022011A1/en not_active Abandoned
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/en not_active Ceased
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/en active Pending
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/en not_active Abandoned
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/en active Pending
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/en not_active Withdrawn
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/en active Active
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/en not_active IP Right Cessation
- 2017-05-02 TW TW106114551A patent/TW201741286A/en unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296B1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/en unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/en unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200317621A1 (en) | 2020-10-08 |
| EA201892341A1 (en) | 2019-05-31 |
| CN109414425A (en) | 2019-03-01 |
| BR112018072439A2 (en) | 2019-02-19 |
| EP3452035A1 (en) | 2019-03-13 |
| PH12018502296B1 (en) | 2022-04-06 |
| ES2886495T3 (en) | 2021-12-20 |
| KR20190005904A (en) | 2019-01-16 |
| JP2019514905A (en) | 2019-06-06 |
| TW201741286A (en) | 2017-12-01 |
| AR108257A1 (en) | 2018-08-01 |
| WO2017192451A1 (en) | 2017-11-09 |
| MX2018013349A (en) | 2019-02-20 |
| SG11201809471UA (en) | 2018-11-29 |
| PH12018502296A1 (en) | 2019-07-08 |
| EP3452035A4 (en) | 2019-09-25 |
| EP3939966A1 (en) | 2022-01-19 |
| AU2017261218A1 (en) | 2018-11-29 |
| IL262578A (en) | 2018-12-31 |
| US20190152923A1 (en) | 2019-05-23 |
| CA3022011A1 (en) | 2017-11-09 |
| MX382095B (en) | 2025-03-13 |
| MA44880A (en) | 2021-03-17 |
| CL2018003109A1 (en) | 2019-04-26 |
| US10626092B2 (en) | 2020-04-21 |
| EP3452035B1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019008783A2 (en) | Cyclic dinucleotide compounds for the treatment of cancer | |
| CL2019001744A1 (en) | Benzoxazole derivatives as immunomodulators. | |
| CO2019000386A2 (en) | Heterocyclic compounds as immunomodulators | |
| CO2018007528A2 (en) | Heterocyclic compounds as immunomodulators | |
| CO2018005954A2 (en) | Heteroaromatic compounds as btk inhibitors | |
| ECSP17073743A (en) | K-RAS MODULATORS | |
| CO2017005784A2 (en) | Fused bicyclic compounds for the treatment of diseases | |
| CO2017001884A2 (en) | Polymorphs of selinexor | |
| DOP2016000144A (en) | GPR6 TETRAHYDROPIRIDOPIRAZIN MODULATORS | |
| UY34657A (en) | ? MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES ?. | |
| CO2017007121A2 (en) | Fused bicyclic compounds for the treatment of diseases | |
| DOP2018000040A (en) | 2-AMINO-3-FLUORO-3- (FLUOROMETIL) -6-METI-6-PHENYL-3,4,5,6-TETRAHYDROPIRIDINES AS BACE INHIBITORS1 | |
| ECSP18012103A (en) | COLONY STIMULATING FACTOR RECEPTOR 1 (CSF-1R) INHIBITORS | |
| CL2016002091A1 (en) | Triazine compound and its use for medicinal purposes | |
| CR20170005A (en) | INSOINDOLINE DERIVATIVES | |
| HUE051296T2 (en) | Benzoxazinone derivatives for the treatment of skin diseases | |
| CL2018001085A1 (en) | Indolin-2-one derivatives | |
| CO2018012941A2 (en) | Polymorphic forms of 3- [2-butyl-1- (2-diethylamino-ethyl-1h-benzoimidazol-5-yl] -n-hydroxy-acrylamide and their uses | |
| UY36221A (en) | ISOINDOLINONE DERIVATIVES | |
| MX2018008895A (en) | 2-oxindole compounds. | |
| CO2017010621A2 (en) | Fused bicyclic compounds for the treatment of diseases | |
| UY36217A (en) | PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE. | |
| IL262801A (en) | History of 2-anilinopyrimidine as medicinal agents for the treatment of brain cancers | |
| MX2017008373A (en) | Compounds, compositions and methods. | |
| LT3519050T (en) | COMPOSITIONS FOR THE TREATMENT OF OPHTHALMOLOGICAL CONDITIONS |